BioSpace News Archive

Drug Development

Pfizer’s Ritlecitinib Stops Alopecia Areata In Its Tracks

Pfizer said that the Phase IIb/III ALLEGRO trial on ritlecitinib was found to be effective against the autoimmune disease, which is characterized by an immune attack on hair follicles.

August 4, 2021
·
2 min read
·
Vanessa Doctor, RN
Business

Schrödinger and Zai Lab Partner in Innovative Precision Oncology Space

Schrödinger and Zai Lab have announced a worldwide development and commercialization collaboration to advance a novel oncology program targeting the DNA damage repair pathway.

August 4, 2021
·
2 min read
·
Brandon May
Business

SoftBank Acquires $5 Billion Stake in Roche

With the acquisition of the Roche stake, SoftBank has become one of the company’s biggest stakeholders.

August 4, 2021
·
2 min read
·
Alex Keown
BioForest

Sonoma Scores $265 Million to Restore Immune System Balance

Sonoma BioTherapeutics continues to work toward its goal of restoring immune system balance through complementary regulatory T cell therapy and effector T cell conditioning, this time with the help of an oversubscribed Series B round.

August 4, 2021
·
2 min read
·
Ellen Bombela
Job Trends

355 New Jobs for NC as Amgen Announces New Holly Springs Biologics Site

The new $550 million site in N.C. follows the advanced packaging plant in Ohio that will significantly expand the company’s manufacturing capacity in the U.S.

August 4, 2021
·
2 min read
·
Alex Keown
Business

AbCellera to Collaborate with Tachyon, EQRx on Therapeutic Antibodies for Cancer

The company struck two separate collaborations over the past two days in order to advance the development of new, innovative medications.

August 4, 2021
·
3 min read
·
Alex Keown
Policy

AbbVie’s Humira Sales Drop Internationally from Biosimilar Competition, but Not in the U.S.

Biosimilars have gained traction in Europe, but not in the U.S. AbbVie’s Humira is often made as an example of how companies are using legal tactics to delay biosimilar competition.

August 4, 2021
·
3 min read
·
Mark Terry
Business

Ardelyx to Cut a Third of Workforce in Fallout from Surprise FDA Rejection

Ardelyx indicates the restructuring plan will save $17 million in annual cash compensation although there will be a restructuring charge of about $3.4 million.

August 4, 2021
·
2 min read
·
Mark Terry
Policy

Syntec Runs Afoul of FDA with Several GMP Infractions

Specifically, the FDA states Syntec has critical issues with how the pharmaceutical manufacturer handles active pharmaceutical ingredients, issues that may compromise the safety of the firm’s manufactured drugs.

August 4, 2021
·
2 min read
·
Brandon May
Business

Biofacturing Firm Posts Loss Just Three Months After IPO, CEO Steps Down

Shares of Zymergen plummeted by 68% Tuesday from its April IPO price of $31 per share to just $11.7 per share after news that the company will not likely see revenue anytime soon.

August 4, 2021
·
2 min read
·
Vanessa Doctor, RN